The CapitalBio Respiratory Pathogens Nucleic Acid Detection Kit can rapidly test for the presence of several types of common respiratory bacterial pathogens directly in respiratory secretions or aspirated samples. The respiratory bacterial pathogens detection kit greatly reduces the time of clinical diagnosis, improves its accuracy and facilitates appropriate treatment. It also avoids problems associated with some bacteria that are difficult to culture. It is an effective tool for the rapid detection of infectious diseases, delivery of precision treatment and coping with major public health emergency. In 2015, the Nucleic Acid Kit passed the special approval procedure for innovative medical apparatus and instruments by the China Food and Drug Administration.